Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Testosterone: Functions and Regulation

Testosterone: Functions and Regulation

The intricate hormonal interplay essential for male reproductive health begins with the release of gonadotropin-releasing hormone (GnRH) by the hypothalamus. This hormone prompts the pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). LH targets the Leydig cells in the testes, stimulating them to produce and release testosterone. In concert with testosterone, FSH acts on the Sertoli cells within the seminiferous tubules to facilitate the release of...

Menopause

Menopause

Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...

Signs of Puberty

Signs of Puberty

Puberty is a critical phase, typically beginning between the ages of 8 and 13 in girls and 9 and 14 in boys, though timing can vary based on genetics, environmental factors, and overall health. This period is characterized by the development of secondary sexual characteristics and the attainment of reproductive potential. Endocrine changes underpin puberty, with hormonal surges of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) instigated by Gonadotropin-Releasing Hormone (GnRH)...

Disorders of the Male Reproductive System

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....

Infertility in Males

Infertility in Males

Male infertility affects millions of couples worldwide, arising from various factors that impact different stages of the reproductive process. An endocrine imbalance resulting from conditions like hypogonadism, Klinefelter syndrome, or pituitary disorders can disrupt hormone levels and reduce sperm production. Testicular defects, such as tumors, cryptorchidism, atrophic testes, abnormal sperm morphology, and low sperm count or motility, may arise due to genetic factors, structural...

Overview of the Reproductive System

Overview of the Reproductive System

The reproductive system generates offspring, ensuring the survival of the species. In humans, the reproductive system is complex and involves a variety of organs and hormones that work together to ensure successful reproduction.
The gonads, or primary reproductive organs, produce gametes and sex hormones. In males, the testes produce spermatozoa and testosterone, which is responsible for developing secondary male sex characteristics, including a deeper voice, larger muscles, facial and body...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Normal spermatogenesis in older men is associated with compensatory transcriptome changes.

GeroScience·2026

Same author

Translation and cultural adaptation of the GENDER-Q with pilot implementation among patients undergoing masculinizing chest surgery.

Journal of plastic, reconstructive & aesthetic surgery : JPRAS·2026

Same author

The association between age and mortality in men with adult-onset testosterone deficiency is altered by testosterone therapy.

The aging male : the official journal of the International Society for the Study of the Aging Male·2026

Same author

Can Hormonal Therapy Improve the Outcomes of mTESE in Patients With Non-Obstructive Azoospermia?

Andrology·2026

Same author

Cryopreservation of Spermatozoa Prior and Post-Orchiectomy in Patients With Testicular Germ Cell Cancer-Does the Timing Matter?

Andrology·2026

Same author

Diagnosis and management of male hypogonadism in Germany.

The aging male : the official journal of the International Society for the Study of the Aging Male·2025

Search research articles

Related Experiment Video

Updated: Jun 30, 2025

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

TRACK_9: Testosterone replacement assessment: Classical vs. functional hypogonadism-knowledge from a 9-year study.

Michael Zitzmann¹, Jann-Frederik Cremers¹, Claudia Krallmann¹

¹Centre of Reproductive Medicine and Andrology of the University, Muenster, Germany.

|March 15, 2024

Summary

Testosterone Therapy (TTh) shows varied long-term effects in hypogonadal men. Functional hypogonadism (FH) patients experienced greater weight loss and improved symptoms, but also higher risks for elevated hematocrit and PSA levels compared to classical hypogonadism (CH).

Keywords:

classical hypogonadism functional hypogonadism testosterone testosterone therapy

More Related Videos

Author Spotlight: Advancing Human Ovarian Repair and Cancer Studies with Surface Epithelium Organoids

Author Spotlight: Advancing Human Ovarian Repair and Cancer Studies with Surface Epithelium Organoids

Published on: August 16, 2024

A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome

A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome

Published on: October 2, 2018

Related Experiment Videos

Last Updated: Jun 30, 2025

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

Author Spotlight: Advancing Human Ovarian Repair and Cancer Studies with Surface Epithelium Organoids

Author Spotlight: Advancing Human Ovarian Repair and Cancer Studies with Surface Epithelium Organoids

Published on: August 16, 2024

A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome

A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome

Published on: October 2, 2018

Area of Science:

Endocrinology
Men's Health
Clinical Research

Background:

Longitudinal data on Testosterone Therapy (TTh) for functional hypogonadism (FH) is limited.
Understanding TTh's efficacy across different hypogonadal etiologies is crucial.

Purpose of the Study:

To evaluate the long-term efficacy and clinical utility of TTh in men with FH.
To compare TTh outcomes between FH and classical hypogonadism (CH) patients.

Main Methods:

A 9-year registry study of 650 hypogonadal men.
Included 188 FH patients and 462 CH patients (primary and secondary hypogonadism).
All patients received intramuscular testosterone undecanoate (1,000 mg); comparative analysis of anthropometric, metabolic, and safety parameters.

Main Results:

TTh increased serum testosterone levels and led to weight and waist circumference reduction in both FH and CH groups.
FH patients showed greater weight/waist reduction but also higher risks for hematocrit and PSA increases.
FH patients exhibited more pronounced improvements in metabolic parameters and symptom scores (AMS, IIEF-EF).

Conclusions:

Therapeutic outcomes of TTh are heterogeneous across hypogonadal populations.
Responses are significantly influenced by diagnostic category, age, and baseline risk factors.
TTh's impact is modulated by age and initial weight, with notable differences between FH and CH.